Preexisting vs. de novo antibodies against SARS-CoV-2 in individuals without or with virus infection: impact on antibody therapy, vaccine research and serological testing.

Autor: Muthumani K; GeneOne Life Science, Inc, Seoul, 07335 South Korea., Xu Z; Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104 USA., Jeong M; GeneOne Life Science, Inc, Seoul, 07335 South Korea., Maslow JN; GeneOne Life Science, Inc, Seoul, 07335 South Korea.; Department of Medicine, Morristown Medical Center, Morristown, NJ 07960 USA., Kalyanaraman VS; IDC Diagnostics, Rockville, MD 20852 USA., Srinivasan A; NanoBio Diagnostics, West Chester, PA 19382 USA.
Jazyk: angličtina
Zdroj: Translational medicine communications [Transl Med Commun] 2021; Vol. 6 (1), pp. 13. Date of Electronic Publication: 2021 Jul 01.
DOI: 10.1186/s41231-021-00093-2
Abstrakt: The causative agent of the ongoing pandemic in the world is SARS-CoV-2. The research on SARS-CoV-2 has progressed with lightning speed on various fronts, including clinical research and treatment, virology, epidemiology, drug development, and vaccine research. Recent studies reported that sera from healthy individuals, who were confirmed negative for SARS-CoV-2 by RT-PCR method, tested positive for antibodies against spike and nucleocapsid proteins of SARS-CoV-2. Further, such antibodies also exhibited neutralizing activity against the virus. These observations have prompted us to prepare a commentary on this topic. While the preexisting antibodies are likely to protect against SARS-CoV-2 infection, they may also complicate serological testing results. Another unknown is the influence of preexisting antibodies on immune responses in individuals receiving vaccines against  SARS-CoV-2. The commentary identifies the potential limitations with the serological tests based on spike and nucleocapsid proteins as these tests may overestimate the seroprevalence due to cross-reactive antibodies. The inclusion of tests specific to SARS-CoV-2 (such as RBD of spike protein) could overcome these limitations.
Competing Interests: Competing interestsThe authors declare no competing financial interest.
(© The Author(s) 2021.)
Databáze: MEDLINE
Externí odkaz: